Lilly Sues Six Firms Over Unauthorized Sales of Experimental Obesity Drug

Eli Lilly has initiated legal action against six U.S. companies for allegedly selling retatrutide, an investigational diabetes and weight-loss drug not yet approved by regulators. The lawsuits mark the first time Lilly has taken such steps to combat what it describes as a black market for the unapproved medication. Retatrutide remains in clinical trials, and the company is seeking to halt unauthorized distribution.